OncBioMune Announces Term Sheet to Acquire Norepinefrine from Teva Pharmaceuticals in Mexico


OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the signing of a non-binding term sheet (“Term Sheet”) with NYSE-listed Teva Pharmaceuticals Industries Ltd. (“Teva”), the world’s largest generic medicines producer, with regards to Norepinefrine for the Mexican market. This registration can as well be used in other Central and Latin American countries and will be selected by own discretion.

The term sheet confirms mutual interest and sets forth guidelines for OncBioMune to acquire the sanitary registration and intellectual property rights of Norepinefrine currently owned by Teva. Norepinefrine is approved in Mexico as indicated for the treatment of low blood pressure and heart failure. Keep Reading

OncBioMune Pharmaceuticals is on it’s way to the ‘Holy Grail’ of Cancer Treatment


From a global perspective, spending on oncology drugs climbed 10.3% in 2014 to $100 billion, up from $75 billion five years ago

“The increased prevalence of most cancers, earlier treatment initiation, new medicines, and improved outcomes are all contributing to the greater demand for oncology therapeutics around the world,” says Murray Aitken, IMS Health senior vice president and executive director of the IMS Institute for Healthcare Informatics.

Many smaller companies in this sector are still in the research and development phase, with no approved drugs yet on the market or any actual earnings.

Companies that are working on cancer immunotherapy can be broken up into two main categories. First are the large pharmaceutical companies that are bringing the first generation of these immunotherapy drugs to market, including MRK, BMY, and Amgen (AMGN). The second category includes smaller biotechnology companies that are working on the second- and third-generation immunotherapy technologies that may reach the market in the years ahead. Keep Reading

Versus Systems inc (OTC:VRSSF) Could Be a Major Player in The $600 Billion Dollars Advertising & Gaming Industry


The Company is developing a software platform that allows video game publishers and developers to offer prize-based matches and tournaments of The Company is developing a software platform that allows video game publishers and developers to offer prize-based matches and tournaments their games. This proprietary technology is being integrated into select games that are planned to be in market in early 2017.

Company Website : http://www.versussystems.com/

We’ve developed a white-label platform that allows video game publishers and developers to integrate prize-based matches into their games. We work behind the scenes to bring players the opportunity to play their favorite games for prizes they love – everything from downloadable content, to physical goods, to real money. We have multiple patent claims pending both in the US and internationally, covering player identification, match management, and prize distribution. Keep Reading

Cell MedX Corp. is an early development stage biotech company focused on diabetes, Parkinson’s disease, high blood pressure


Cell MedX Corp. (OTCQB: CMXC) is an early development stage biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure.

The company develops technologies to help and manage the illness and related complications. Its Cell MedX’s proprietary technology is the “e-balance eBalance technology”, which is in the research and development stage to manage diabetes mellitus and its complications.

The company has some solid cash reserves on the balance sheet, and recently cut over $800k off its current liabilities between its last two reporting periods. The company recently cut over $800k off its current liabilities between its last two reporting periods by converting those liabilities to stock ownership.

CMXC also began to move forward with renewed focus after divesting its Avyonce Cosmedics segment in late January. In our experience, that tends to foster greater success in primary segments, particularly in biotech ventures.
Keep Reading

This Stock Could Benefit From TESLA’s Plan To Produce 35 Gigawatt Hours Of Lithium-ion Batteries Per Year

in NASDAQ by

A massive new factory could be producing lithium-ion batteries, the energy source for electric cars, in Europe by 2020, if plans for a Nordic “gigafactory” come to fruition.

Peter Carlsson and Paolo Cerruti, both ex-executives for Tesla, the electric car pioneer owned by Elon Musk, today announced  that they plan to build a $4 billion factory to manufacture the batteries, most likely in Sweden but possibly in Finland.

Musk himself is in the middle of building a giant battery factory in the Nevada desert. That factory is to produce 35 gigawatt hours of lithium-ion batteries per year when it’s completed in 2018.

So far there’s been nothing to match the plans elsewhere and certainly nothing in Europe. Companies based in South Korea, Japan, and China are the current market leaders in lithium-ion battery production.

Carlsson and Cerrutri’s company, Northvolt, wants to match the Tesla gigafactory output. Northolt so far has obtained inancing from Vattenfall, Sweden’s state-owned utility, Swedish conglomerate Stena, and the Swedish Energy Agency, reports the Financial Times (paywall). Carlsson told the FT that there is “tremendous interest” in the $4 billion factory, but didn’t say how the project would be financed.

A Nordic base could help the project source much of its energy from renewables, and provide access to raw materials. Cobalt and nickel are both mined in Finland, and the region has been pioneering in low carbon energy from wind, hydro, and geothermal sources.

LITH (U.S. Lithium Corp.) is an exploration and development company focused in North America on lithium and related resources for the rapidly growing energy storage industry. The Company looks to capitalize on opportunities within the lithium sector including providing lithium to the ever expanding next generation battery market. Keep Reading

Featured Small Cap Of The Month ( UP To 100% Short Term Gain Potential )


2 BIG NAMES INVOLVED IN $SPYR : Facebook inc (NASDAQ:FB) & Electronic Arts inc (NASDAQ:EA)

SPYR Hires Former Electronic Arts (EA) Executive As Chief Strategic AdvisorFacebook’s Almost 2 Billion Active Users Offers SPYR Huge Opportunity to Grow Pocket Starships’ User Base

Facebook Adds SPYR’s Pocket Starships to New Gameroom Platform


 SPYR inc (SPYR) Is A 70 Cent Trading Opportunity With +100pct in UPSIDE POTENTIAL! This is based on the fact that it was trading as high as $1.06 just last month!

(SPYR) Has Been Seriously Known To Make MONSTER RUNS UP! Keep Reading

Caterpillar inc (NYSE:CAT) : Option Calls With UP To 100% Gain Potential

in NYSE by

Stocks near all time highs often instill the presumptive “adjustment and anchoring bias” in the minds of investors. This principle works on the belief that investors use the all time high price as a reference point and value stocks against this anchor.

Many a times such stocks are prevented from scaling higher despite robust potential due to the psychological bias of investors who fear that the stocks are overvalued and a price crash is impending.

A few of the stocks remain undervalued due to prolonged under reaction on part of investors, despite bullish growth drivers. Meanwhile, news pertaining to robust sales, surging profit levels, bullish earnings prospects and strategic acquisitions can drive the stock higher. Keep Reading

SPYR Hires Former Electronic Arts (EA) Executive As Chief Strategic Advisor


SPYR, INC. (OTCQB: SPYR), a holding company with wholly owned subsidiaries in both the mobile game & app development and publishing industry, and in the restaurant industry, today announced that Farshid Almassizadeh, the former VP and COO of EA Interactive, will join the SPYR team as its Chief Strategic Advisor.  Mr. Almassizadeh will bring his 25+ years of experience in the gaming industry to SPYR as an advisor to SPYR’s management team, the game publishing team, as well as the associated developer community. Keep Reading

Wanderport Corp (OTC:WDRP) Has Over 1000% Upside Potential

Wanderport Corp (OTC:WDRP) is positioned to become the next mega-winner in that industry
Current Price : 0.013
Target (2017) : 0.13
OVER 1000% Price Surge Could Be Right In Front Of You…
 Cannabis stocks are some of the most explosive stocks in the world – they have
rewarded their investors with quadruple-digit gains during 2016.
GreenGro Technologies, Inc. rallied 1,100% within one month.
American Green Inc. rallied 2,000% within three.
Cannabis Science, Inc. rallied 1,500% within one month.
Medical Marijuana, Inc. rallied 1,400% within one year.
Totally Hemp Crazy Inc. rallied 3,100% within three months.
Growlife, Inc. rallied 1,400% within one year.
Cannabis Sativa, Inc. rallied 1,200% within one month.

Keep Reading

SPYR inc (OTC:SPYR) Could Be a Major Player in The Multi Billions Dollars Mobile Games Industry


According to the company’s materials, “SPYR, INC. is a holding company that through its wholly owned subsidiary SPYR APPS, LLC, is engaged in mobile application and game publishing and development. SPYR, INC. also owns and operates an “American Diner” theme restaurant located in the Philadelphia International Airport in Philadelphia, Pennsylvania called “Eat at Joe’s” through its other wholly-owned subsidiary, E.A.J.: PHL Airport Inc. The Company is currently exploring opportunities for additional acquisitions in these and other verticals, including mobile application and game development, to expand its holdings, to drive and increase revenue and to generate profits and build value for shareholders.” Keep Reading

1 2 3 12
Go to Top